title: Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.
abstract: Anticancer drugs that bind to DNA and inhibit DNA-processing enzymes represent an important class of anticancer drugs. Combilexin molecules, which combine DNA minor groove binding and intercalating functionalities, have the potential for increased DNA binding affinity and increased selectivity due to their dual mode of DNA binding. This study describes the synthesis of DNA minor groove binder netropsin analogs containing either one or two N-methylpyrrole carboxamide groups linked to DNA-intercalating anthrapyrazoles. Those hybrid molecules which had both two N-methylpyrrole groups and terminal (dimethylamino)alkyl side chains displayed submicromolar cytotoxicity towards K562 human leukemia cells. The combilexins were also evaluated for DNA binding by measuring the increase in DNA melting temperature, for DNA topoisomerase IIalpha-mediated double strand cleavage of DNA, for inhibition of DNA topoisomerase IIalpha decatenation activity, and for inhibition of DNA topoisomerase I relaxation of DNA. Several of the compounds stabilized the DNA-topoisomerase IIalpha covalent complex indicating that they acted as topoisomerase IIalpha poisons. Some of the combilexins had higher affinity for DNA than their parent anthrapyrazoles. In conclusion, a novel group of compounds combining DNA intercalating anthrapyrazole groups and minor groove binding netropsin analogs have been designed, synthesized and biologically evaluated as possible novel anticancer agents.
authors.affiliation: Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0T5.
authors.forename: Rui
authors.initials: R
authors.lastname: Zhang
authors.forename: Xing
authors.initials: X
authors.lastname: Wu
authors.forename: Lynn J
authors.initials: LJ
authors.lastname: Guziec
authors.forename: Frank S
authors.initials: FS
authors.lastname: Guziec
authors.forename: Gaik-Lean
authors.initials: GL
authors.lastname: Chee
authors.forename: Jack C
authors.initials: JC
authors.lastname: Yalowich
authors.forename: Brian B
authors.initials: BB
authors.lastname: Hasinoff
mesh_terms: D000577:Amides / Q000138:chemical synthesis* / Q000494:pharmacology; D018943:Anthracyclines / Q000138:chemical synthesis / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D004247:DNA / Q000737:chemistry / Q000378:metabolism*; D015195:Drug Design; D006801:Humans; D007364:Intercalating Agents; D020014:K562 Cells; D009429:Netropsin; D011758:Pyrroles
chemical_list: D000577:Amides; D018943:Anthracyclines; D000970:Antineoplastic Agents; D007364:Intercalating Agents; D011758:Pyrroles; D009429:Netropsin; D004247:DNA; C055925:anthrapyrazole
references.citation: Prog Nucleic Acid Res Mol Biol. 2000;64:221-53
references.pmid: 10697411
references.citation: Bioorg Med Chem. 2009 Jul 1;17(13):4575-82
references.pmid: 19457675
references.citation: J Pharm Sci. 1989 Nov;78(11):910-7
references.pmid: 2621573
references.citation: Cancer Chemother Pharmacol. 2006 Jan;57(2):221-33
references.pmid: 16010589
references.citation: Biochem Pharmacol. 1997 Jun 15;53(12):1843-53
references.pmid: 9256159
references.citation: Curr Med Chem. 2005;12(24):2805-47
references.pmid: 16305474
references.citation: Chem Res Toxicol. 1993 Sep-Oct;6(5):585-97
references.pmid: 8292734
references.citation: Br J Cancer. 1994 Apr;69(4):687-97
references.pmid: 8142256
references.citation: Chembiochem. 2003 Jan 3;4(1):50-61
references.pmid: 12512076
references.citation: Anticancer Drug Des. 1995 Mar;10(2):131-54
references.pmid: 7710635
references.citation: J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35
references.pmid: 16859314
references.citation: Bioorg Med Chem. 2008 Apr 1;16(7):3959-68
references.pmid: 18258442
references.citation: Acta Crystallogr D Biol Crystallogr. 1995 Mar 1;51(Pt 2):190-8
references.pmid: 15299320
references.citation: Biochem Pharmacol. 1996 Aug 23;52(4):635-42
references.pmid: 8759037
references.citation: Biochem Pharmacol. 1988 Dec 15;37(24):4727-33
references.pmid: 2462423
references.citation: Methods Enzymol. 2001;340:529-55
references.pmid: 11494869
references.citation: Mol Pharmacol. 2008 Mar;73(3):686-96
references.pmid: 18045852
references.citation: Biochem Pharmacol. 2004 Feb 15;67(4):631-42
references.pmid: 14757163
references.citation: Anticancer Drug Des. 1997 Sep;12(6):481-501
references.pmid: 9311557
references.citation: J Natl Cancer Inst. 1994 Aug 17;86(16):1239-44
references.pmid: 8040892
references.citation: Arch Biochem Biophys. 1995 Aug 1;321(1):51-60
references.pmid: 7639535
references.citation: Proteins. 2003 Sep 1;52(4):609-23
references.pmid: 12910460
references.citation: Mol Pharmacol. 1997 Nov;52(5):839-45
references.pmid: 9351975
references.citation: Mol Pharmacol. 1994 Jul;46(1):58-66
references.pmid: 8058057
references.citation: Mol Pharmacol. 1996 Feb;49(2):343-50
references.pmid: 8632768
references.citation: Bioconjug Chem. 1998 Sep-Oct;9(5):513-38
references.pmid: 9736486
references.citation: J Mol Biol. 1994 Jan 28;235(4):1218-30
references.pmid: 8308885
references.citation: Methods Mol Biol. 2001;95:283-9
references.pmid: 11089240
references.citation: Annu Rev Pharmacol Toxicol. 2001;41:53-77
references.pmid: 11264450
references.citation: Eur J Med Chem. 2007 Jun;42(6):752-71
references.pmid: 17433851
references.citation: Acta Crystallogr D Biol Crystallogr. 1993 Sep 1;49(Pt 5):458-67
references.pmid: 15299505
references.citation: Biopolymers. 1976 Jul;15(7):1345-75
references.pmid: 949539
references.citation: Biochim Biophys Acta. 1998 Oct 1;1400(1-3):83-105
references.pmid: 9748515
references.citation: Biochemistry. 1996 Apr 9;35(14):4251-64
references.pmid: 8605173
references.citation: Mol Pharmacol. 2005 Mar;67(3):937-47
references.pmid: 15602006